6 September 2023
Antibodies | Highly Cited Papers in 2021–2022

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
1. “Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong and Aaron M. D’Antona
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13
2. “Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25
3. “Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis and Sophie Papa
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10
4. “Introduction to Antibody-Drug Conjugates”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
Available online: https://www.mdpi.com/2073-4468/10/4/42
5. “Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann and Nicholas Jones
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17
6. “Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective”
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Antibodies 2021, 10(3), 30; https://doi.org/10.3390/antib10030030
Available online: https://www.mdpi.com/2073-4468/10/3/30
7. “From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36
8. “Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies”
by Brian A. Baldo
Antibodies 2022, 11(1), 17; https://doi.org/10.3390/antib11010017
Available online: https://www.mdpi.com/2073-4468/11/1/17
9. “Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS”
by Emmanuel J. Favaloro, Leonardo Pasalic and Giuseppe Lippi
Antibodies 2022, 11(1), 7; https://doi.org/10.3390/antib11010007
Available online: https://www.mdpi.com/2073-4468/11/1/7
10. “Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle?”
by Snezhina Lazova, Yulia Dimitrova, Diana Hristova, Iren Tzotcheva and Tsvetelina Velikova
Antibodies 2022, 11(2), 25; https://doi.org/10.3390/antib11020025
Available online: https://www.mdpi.com/2073-4468/11/2/25